Trial Profile
A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Temsirolimus (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 05 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Dec 2013 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.